Min Xu
Brookline, MANPI 1922212471
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,268, 4.2 times the $301 reported in 2019.
Across 81 payments — averaging $38.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$416
- Medtronic$399
- Ferring Pharmaceuticals Inc.$390
- Endo Pharmaceuticals Inc.$276
- Urogen Pharma, Inc.$264
- Astellas Pharma US Inc$260
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,03497%
- Education$993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 7 | $416 |
| Medtronic(2 entities) | 10 | $399 |
| Ferring Pharmaceuticals Inc. | 7 | $390 |
| Endo Pharmaceuticals Inc. | 8 | $276 |
| Urogen Pharma, Inc. | 4 | $264 |
| Astellas Pharma US Inc | 8 | $260 |
| Sumitomo Pharma America, Inc. | 6 | $178 |
| Telix Pharmaceuticals | 6 | $130 |
| Janssen Scientific Affairs, LLC | 1 | $123 |
| AbbVie | 4 | $106 |
| Blue Earth Diagnostics | 4 | $94 |
| Myovant Sciences Inc. | 1 | $91 |
| Boston Scientific | 3 | $85 |
| Progenics Pharmaceuticals, Inc. | 3 | $83 |
| Endo USA, Inc. | 3 | $74 |
| Convatec Inc. | 1 | $49 |
| Merck | 1 | $30 |
| 180 Medical, Inc. | 1 | $28 |
| Myriad Genetic Laboratories, Inc. | 1 | $21 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $20 |
| Pfizer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 33 | $431 |
| Finasteride | 18 | $302 |
| Cephalexin | 11 | $49 |
| Oxycodone Hcl | 19 | $31 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.